Introduction {#cdr12174-sec-0005}
============

Warfarin, a vitamin K antagonist, is an effective [1](#cdr12174-bib-0001){ref-type="ref"}, [2](#cdr12174-bib-0002){ref-type="ref"} and commonly prescribed drug for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). However, there are considerable challenges associated with warfarin treatment [3](#cdr12174-bib-0003){ref-type="ref"}, [4](#cdr12174-bib-0004){ref-type="ref"}, [5](#cdr12174-bib-0005){ref-type="ref"}, [6](#cdr12174-bib-0006){ref-type="ref"}. Indeed, patients prescribed warfarin need to maintain a narrow therapeutic level of anticoagulation measured by the international normalized ratio (INR). Patients who are underanticoagulated are at increased risk for stroke and those who are overanticoagulated are at increased risk for bleeding [7](#cdr12174-bib-0007){ref-type="ref"}. This risk may be reduced with the introduction of the novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), which have similar or lower rates of thrombotic events compared with warfarin and are associated with a similar or lower risk of bleeding [8](#cdr12174-bib-0008){ref-type="ref"}, [9](#cdr12174-bib-0009){ref-type="ref"}, [10](#cdr12174-bib-0010){ref-type="ref"}, [11](#cdr12174-bib-0011){ref-type="ref"}, [12](#cdr12174-bib-0012){ref-type="ref"}, [13](#cdr12174-bib-0013){ref-type="ref"}, [14](#cdr12174-bib-0014){ref-type="ref"}.

In the real‐world setting, warfarin is often underused for stroke prevention in patients with atrial fibrillation (AF) who are eligible for oral anticoagulant treatment [14](#cdr12174-bib-0014){ref-type="ref"}, [15](#cdr12174-bib-0015){ref-type="ref"}, [16](#cdr12174-bib-0016){ref-type="ref"}, [17](#cdr12174-bib-0017){ref-type="ref"}. One factor that influences the underuse of warfarin is concern about the increased risk for bleeding [18](#cdr12174-bib-0018){ref-type="ref"}, [19](#cdr12174-bib-0019){ref-type="ref"}; however, discontinuing or interrupting warfarin treatment for any reason may increase the risk for ischemic stroke [8](#cdr12174-bib-0008){ref-type="ref"}, [20](#cdr12174-bib-0020){ref-type="ref"}.

It is important to identify and try to prevent events that may lead to warfarin discontinuation in these patients [21](#cdr12174-bib-0021){ref-type="ref"}, [22](#cdr12174-bib-0022){ref-type="ref"}. To our knowledge, no observational study has yet evaluated the association between bleeding events and subsequent warfarin discontinuation in patients with AF. Thus, the objective of this study was to quantify the association of bleeding events and subsequent warfarin discontinuation in patients with NVAF.

Methods {#cdr12174-sec-0006}
=======

Data Source {#cdr12174-sec-0007}
-----------

This study used data from the Optum Research database (Ingenix, Eden Prairie, MN, USA), which includes all paid claims from a large private insurer with more than 35 million members and their dependents across the United States. Members are mostly working individuals under the age of 65 years, but also include those 65 years and older who continue to be insured through their employer\'s insurance. The paid claims for both medical and pharmacy benefits are in this database; claims from capitated plans are included as well.

Each claim in the database contains a unique encrypted patient identifier that is used to assemble a longitudinal record of medical and pharmacy services for each member. Eligibility, year of birth, and sex are available for all members in the database (members missing this information were excluded). Individuals in the database are representative of the national commercially insured population for a variety of demographic measures, including age, sex, geographic region, and health plan type. Data available for each medical claim include: dates of service; location of service; International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnosis codes; physician specialty; and procedure codes in the Physicians' Current Procedural Terminology and the Centers for Medicare and Medicaid provided Common Procedure Coding System. Pharmacy claims include the drug dispensed in National Drug Code format, the date of dispensing, and the quantity and number of therapy‐days dispensed.

Patient Population {#cdr12174-sec-0008}
------------------

We first identified a base cohort of all patients (age ≥18 years) with a new diagnosis of AF (ICD‐9‐CM codes 427.31, 427.32, and 427.3) from 2005 to 2011. A new diagnosis was defined based on the absence of any AF diagnosis in the prior year. We excluded patients with a diagnosis of paroxysmal or valvular AF. We then assembled a study cohort comprising patients who were newly treated with warfarin. Cohort entry was defined by the date of the first warfarin prescription. To be included in the study cohort, patients were required to have at least 1 year of medical history in the database prior to cohort entry, at least 60 days of warfarin treatment, and at least one risk factor for stroke as measured by the CHADS~2~ score (age ≥75 years, prior stroke or transient ischemic attack \[TIA\], congestive heart failure \[CHF\], diabetes, and/or hypertension) in the year prior to cohort entry. Patients with a history of mitral valve prolapse or aortic valve replacement in the year prior to AF diagnosis were excluded.

All patients were followed up from study cohort entry (date of the first warfarin prescription) to the first of the following events: treatment discontinuation (defined by a treatment gap of at least 60 days), death from any cause, end of coverage, or end of the study period (December 31, 2011).

Study Design {#cdr12174-sec-0009}
------------

A nested case--control analysis was conducted within the study cohort defined above to evaluate the relationship between bleeding and warfarin discontinuation. Cases were patients who discontinued warfarin treatment during follow‐up, with the index date set as the date of discontinuation (Figure [1](#cdr12174-fig-0001){ref-type="fig"}). For each case, up to 10 controls were randomly selected from a case\'s risk set and matched to the case on age (±10 years), sex, and duration of follow‐up (which corresponded to warfarin treatment duration). A sampling with replacement method was used. The controls inherited the index date of their matched cases. In the risk‐set sampling, a control could be a case at a later date.

![Study design. Cases and controls were matched on age (±10 years), sex, and duration of warfarin treatment. AF, atrial fibrillation.](CDR-34-94-g001){#cdr12174-fig-0001}

Bleeding Events {#cdr12174-sec-0010}
---------------

Bleeding events were assessed in a 60‐day period prior to index date of discontinuation. These were identified from hospitalized claims confirming in‐patient encounters and were defined by specific ICD‐9‐CM diagnosis codes (Table S1). The ICD‐9‐CM terms included: gastrointestinal hemorrhage, hemorrhage into bladder wall, hemorrhage of prostate, bleeding female genital tract, hemorrhage during pregnancy, hemarthrosis, epistaxis, hemoptysis, intracranial hemorrhage, intracerebral hemorrhage, hemorrhage of thyroid, retinal hemorrhage, and additional bleeding‐related diagnosis codes (Table S1 for complete list). For an individual with multiple bleeding episodes, the bleeding event closest to the index date was selected.

Statistical Analyses {#cdr12174-sec-0011}
--------------------

Descriptive statistics were used to summarize the characteristics of the cohort, cases, and matched controls. In the main analysis, we quantified the odds of discontinuing warfarin as a result of a bleeding event. Conditional logistic regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of warfarin discontinuation associated with bleeding events. All models were adjusted for the following baseline covariates: age, year of cohort entry (i.e., year of warfarin initiation), CHF, hypertension, diabetes, stroke, and TIA, all measured in the year prior to index date. An additional analysis was conducted using CHADS~2~ score as a covariate instead of the individual variables incorporated into the CHADS~2~ score.

Sensitivity Analysis {#cdr12174-sec-0012}
--------------------

A sensitivity analysis was also conducted in which bleeding events were identified only for patients with bleeding listed as the primary diagnosis.

Results {#cdr12174-sec-0013}
=======

Patient Population {#cdr12174-sec-0014}
------------------

Of the 351,636 individuals with a new diagnosis of AF identified in the database, 24,243 met the study inclusion criteria (Figure [1](#cdr12174-fig-0001){ref-type="fig"}). Most cohort members came from older age groups: 1.1% were 18--39 years, 5.1% were 40--49 years, 21.2% were 50--59 years, 33.2% were 60--69 years, and 39.5% were 70 years or older. The majority of patients were male (64.8%). Baseline CHADS~2~ score was 1 in 34.4%, 2 in 32.0%, and ≥3 in 33.5% of individuals. Within the overall cohort, 88.6% had comorbid hypertension, 33.5% had comorbid diabetes, and 32.8% had comorbid CHF. There was a history of stroke in 19.5% of individuals and a history of TIA in 6.7%. Characteristics of cases and controls at index date are shown in Table [1](#cdr12174-tbl-0001){ref-type="table-wrap"}. Cases were generally similar to the controls.

###### 

Characteristics for cases and controls

  Baseline characteristics      Cases    Controls[a](#cdr12174-note-0002){ref-type="fn"}             
  ----------------------------- -------- ------------------------------------------------- --------- -------
  Age, years                                                                                         
  18--39                        178      1.32                                              887       0.66
  40--49                        731      5.42                                              5243      3.89
  50--59                        2949     21.87                                             28,274    20.98
  60--69                        4238     31.43                                             47,135    34.97
  70--79                        2987     22.16                                             32,286    23.96
  80+                           2399     17.79                                             20,951    15.55
  Sex                                                                                                
  Female                        4624     34.3                                              46,219    34.29
  Male                          8858     65.7                                              88,557    65.71
  Year of warfarin initiation                                                                        
  2006                          2557     18.97                                             29,664    22.01
  2007                          2321     17.22                                             25,188    18.69
  2008                          3687     27.35                                             36,230    26.88
  2009                          2351     17.44                                             22,544    16.73
  2010                          2064     15.31                                             16,558    12.29
  2011                          502      3.72                                              4592      3.41
  CHADS~2~ score                                                                                     
  1                             4826     35.8                                              47,439    35.2
  2                             4257     31.58                                             44,131    32.74
  3                             2454     18.2                                              24,862    18.45
  4                             1198     8.89                                              11,834    8.78
  5                             590      4.38                                              5557      4.12
  6                             157      1.16                                              953       0.71
  CHF                                                                                                
  Yes                           4364     32.37                                             41,123    30.51
  No                            9118     67.63                                             93,653    69.49
  Hypertension                                                                                       
  Yes                           11,945   88.6                                              118,874   88.2
  No                            1537     11.4                                              15,902    11.8
  Diabetes                                                                                           
  Yes                           4419     32.78                                             44,763    33.21
  No                            9063     67.22                                             90,013    66.79
  Stroke                                                                                             
  Yes                           2495     18.51                                             26,111    19.37
  No                            10,987   81.49                                             108,665   80.63
  TIA                                                                                                
  Yes                           818      6.07                                              9394      6.97
  No                            12,664   93.93                                             125,382   93.03

CHF, congestive heart failure; TIA, transient ischemic attack.

For each case, up to 10 controls were randomly selected from a case\'s risk set and matched to the case on age (±10 years), sex, and duration of follow‐up (which corresponded to warfarin treatment duration). A sampling with replacement method was used. In the risk‐set sampling, a control could be a case at a later date.
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Among the 24,243 individuals with newly diagnosed AF who met the inclusion criteria, 13,482 had a defined warfarin discontinuation event (index date) within the study period (Figure [2](#cdr12174-fig-0002){ref-type="fig"}).

![Patient schematic. AF, atrial fibrillation; ICD‐9‐CM, International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code. \*For each case, up to 10 controls were randomly selected from a case\'s risk set and matched to the case on age (±10 years), sex, and duration of follow‐up (which corresponded to warfarin treatment duration). A sampling with replacement method was used. In the risk‐set sampling, a control could be a case at a later date.](CDR-34-94-g002){#cdr12174-fig-0002}

The percentage of individuals reporting a bleeding event in the 60 days prior to the index date was higher in cases (individuals with a warfarin discontinuation event) than in controls (individuals without a warfarin discontinuation event). Of the 13,482 cases, 478 individuals (3.55%) had a bleeding event. Among 134,776 controls, 1142 individuals (0.85%) had a bleeding event.

Odds of Discontinuation Associated with Bleeding {#cdr12174-sec-0015}
------------------------------------------------

When comparing patients with and without bleeding events, the unadjusted OR for warfarin discontinuation was 4.30 (95% CI, 3.86--4.79). The results did not change significantly when the definition of discontinuation was changed from 60 days up to 365 days (data not shown). Based on the conditional logistic regression model, the OR for warfarin discontinuation among individuals with a bleed was 4.31 (95% CI, 3.87--4.81; Table [2](#cdr12174-tbl-0002){ref-type="table-wrap"}). Results for individual CHADS~2~ components within this model are provided in Table [2](#cdr12174-tbl-0002){ref-type="table-wrap"}. In an analysis using CHADS~2~ score rather than the components within the CHADS~2~ score, patients with CHADS~2~ scores between 2 and 5 had similar odds of warfarin discontinuation compared with those with CHADS~2~ scores of 1 (OR fell within the range of 0.94--0.98; all 95% CIs included the null value); however, there was a significantly increased risk of warfarin discontinuation in patients with a CHADS~2~ score of 6 compared with those with a CHADS~2~ score of 1 (OR, 1.47 \[95% CI, 1.23--1.75\]).

###### 

Conditional logistic regression model

  Parameter                     Comparison       Odds ratio   95% Confidence limits   
  ----------------------------- ---------------- ------------ ----------------------- ------
  Bleeding                      Unadjusted       4.30         3.86                    4.79
  Adjusted                      4.31             3.87         4.81                    
  Age, years                    18--39 vs. 80+   5.98         4.60                    7.78
  40--49 vs. 80+                1.93             1.68         2.23                    
  50--59 vs. 80+                0.93             0.84         1.03                    
  60--69 vs. 80+                0.71             0.65         0.78                    
  70--79 vs. 80+                0.76             0.71         0.81                    
  Year of warfarin initiation   2007 vs. 2006    1.09         1.02                    1.15
  2008 vs. 2006                 1.21             1.15         1.28                    
  2009 vs. 2006                 1.24             1.17         1.32                    
  2010 vs. 2006                 1.50             1.41         1.60                    
  2011 vs. 2006                 1.34             1.20         1.48                    
  CHF                           Yes vs. no       1.06         1.02                    1.11
  Hypertension                  Yes vs. no       1.05         0.99                    1.11
  Diabetes                      Yes vs. no       0.98         0.94                    1.02
  Stroke                        Yes vs. no       0.97         0.92                    1.02
  TIA                           Yes vs. no       0.89         0.81                    0.97
  CHADS~2~ score                2 vs. 1          0.94         0.90                    0.98
  3 vs. 1                       0.94             0.89         0.99                    
  4 vs. 1                       0.96             0.89         1.03                    
  5 vs. 1                       0.98             0.89         1.08                    
  6 vs. 1                       1.47             1.23         1.75                    

CHF, congestive heart failure; TIA, transient ischemic attack.
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In the sensitivity analysis, including only bleeds as the first listed diagnosis in hospital claims, there were 369 (2.74%) cases and 811 (0.60%) controls reporting bleeding events. The unadjusted OR was 4.64 (95% CI, 4.10--5.26), and the adjusted OR was 4.65 (95% CI, 4.10--5.27).

Discussion {#cdr12174-sec-0016}
==========

Bleeding is often anecdotally reported as a reason for discontinuation of warfarin treatment [18](#cdr12174-bib-0018){ref-type="ref"}, [19](#cdr12174-bib-0019){ref-type="ref"}. Despite fears about bleeding risks with warfarin, few observational studies have been conducted to quantify the association between warfarin use and specific bleeding events. An understanding of how bleeding events impact warfarin discontinuation is important, as interruption of warfarin treatment is associated with an increased risk of thrombotic events in patients with AF compared with those without an interruption of treatment [8](#cdr12174-bib-0008){ref-type="ref"}, [20](#cdr12174-bib-0020){ref-type="ref"}. In this study, there was a higher proportion of individuals with AF who were diagnosed with a bleeding event in the 60 days prior to discontinuing warfarin compared with those who did not discontinue warfarin treatment.

Several studies have evaluated the risk of bleeding associated with antithrombotic agents, specifically warfarin [21](#cdr12174-bib-0021){ref-type="ref"}, [23](#cdr12174-bib-0023){ref-type="ref"}, [24](#cdr12174-bib-0024){ref-type="ref"}. Other studies have evaluated bleeding in the elderly [25](#cdr12174-bib-0025){ref-type="ref"}, [26](#cdr12174-bib-0026){ref-type="ref"}, [27](#cdr12174-bib-0027){ref-type="ref"}. Few studies have evaluated rates of discontinuation in a population with AF treated with an anticoagulant [24](#cdr12174-bib-0024){ref-type="ref"}, [28](#cdr12174-bib-0028){ref-type="ref"}, [29](#cdr12174-bib-0029){ref-type="ref"}. This study evaluated the association between bleeding and discontinuation of warfarin in a large population of individuals with a diagnosis of AF (351,636), of whom 24,243 met the inclusion criteria, which included having a history of at least 60 days of warfarin treatment and at least one CHADS~2~ risk factor for stroke.

One of the limitations of this study was inadequate information in the claims data. This led to some important data not being included in the analysis, including INR values. Additionally, the warfarin discontinuation date (index date) was an approximation calculated by available prescription information. Therefore, the true discontinuation date was unknown and could have been earlier or immediately after the bleeding event. The HAS‐BLED score is an important measure of bleeding risk; however, as data for INR and abnormal renal or liver function were not available in the claims data, it was not possible to examine warfarin discontinuation by HAS‐BLED score.

An additional limitation may be the underestimation of bleeding events; only bleeding events associated with a hospitalization claim, which the authors assume to be the more serious bleeding events, were identified.

The data from this cohort are generalizable to a US population; however, the elderly population may be under‐represented in this cohort. Additional investigation may be needed in patients with AF who are at an advanced age (≥80 years) because they are often considered to be at a higher risk for bleeding, whether or not they are treated with warfarin [28](#cdr12174-bib-0028){ref-type="ref"}, [30](#cdr12174-bib-0030){ref-type="ref"}. The results shown here contribute to the growing body of evidence evaluating the association between warfarin discontinuation and bleeding events in patients with AF. While these analyses do not fully capture all bleeding events during hospitalization, they do suggest that bleeding is significantly associated with warfarin discontinuation.

In conclusion, the association between bleeding events and warfarin discontinuation among patients with AF supports the importance of treatments with a low risk of bleeding.
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